Introduction

Vonoprazan (VPZ), a new potassium-competitive acid blocker, has been shown to be a more potent inhibitor of gastric acid and is able to maintain the intragastric pH above 6 more quickly and for longer than traditional proton pump inhibitors (PPI) (Our previous study included 119 